Published online Jun 9, 2023. doi: 10.5492/wjccm.v12.i3.165
Peer-review started: December 23, 2022
First decision: January 31, 2023
Revised: February 3, 2023
Accepted: March 24, 2023
Article in press: March 24, 2023
Published online: June 9, 2023
Processing time: 167 Days and 0.4 Hours
Ventilator-associated pneumonia (VAP) is defined as pneumonia that occurs two calendar days following endotracheal intubation or after that. It is the most common infection encountered among intubated patients. VAP incidence showed wide variability between countries.
To define the VAP incidence in the intensive care unit (ICU) in the central gove
The research was a prospective cross-sectional observational study over six months from November 2019 to June 2020. It included adult and adolescent patients (> 14 years old) admitted to the ICU and required intubation and mechanical ventilation. VAP was diagnosed when it occurred after 48 h after endotracheal intubation using the clinical pulmonary infection score, which considers the clinical, laboratory, microbiological, and radiographic evidence.
The total number of adult patients admitted to the ICU who required intubation and mechanical ventilation during the study period was 155. Forty-six patients developed VAP during their ICU stay (29.7%). The calculated VAP rate was 22.14 events per 1000 ventilator days during the study period, with a mean age of 52 years ± 20. Most VAP cases had late-onset VAP with a mean number of ICU days before the development of VAP of 9.96 ± 6.55. Gram-negative contributed to most VAP cases in our unit, with multidrug-resistant Acinetobacter being the most identified pathogen.
The reported VAP rate in our ICU was relatively high compared to the international benchmark, which should trigger a vital action plan for reinforcing the implementation of the VAP prevention bundle.
Core Tip: Ventilator-associated pneumonia (VAP) is the most common infection among intubated patients. Early-onset VAP is usually caused by sensitive pathogens, while multidrug-resistant bacteria usually cause late-onset. Early, appropriate, and empirical antibiotics therapy for VAP is crucial to decreasing mortality risk. The VAP rate in Bahrain is relatively high compared to the international rates, which should trigger a vital action plan for reinforcing the implementation of the VAP prevention bundle. Gram-negative bacteria were the most common organisms that cause VAP in the current study, where Acinetobacter baumannii was the most common organism, followed by Klebsiella pneumoniae and Pseudomonas aeruginosa. Knowing the prevalent organisms helps choose the appropriate antibiotics until culture and sensitivity become available.